MA29439B1 - Derives d'uree d'heteroaryle utilises pour inhiber chk1 - Google Patents

Derives d'uree d'heteroaryle utilises pour inhiber chk1

Info

Publication number
MA29439B1
MA29439B1 MA30325A MA30325A MA29439B1 MA 29439 B1 MA29439 B1 MA 29439B1 MA 30325 A MA30325 A MA 30325A MA 30325 A MA30325 A MA 30325A MA 29439 B1 MA29439 B1 MA 29439B1
Authority
MA
Morocco
Prior art keywords
heteroaryle
urea derivatives
derivatives used
inhibit chk1
treatment
Prior art date
Application number
MA30325A
Other languages
English (en)
Inventor
Frank Diaz
Francine S Farouz
Ryan Holcomb
Edward A Kesicki
Hua Chee Ooi
Alexander Rudolph
Frank Stappenbeck
Eugene Thorsett
John Joseph Gaudino
Kimba L Fischer
Adam Wade Cook
Original Assignee
Icos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icos Corp filed Critical Icos Corp
Publication of MA29439B1 publication Critical patent/MA29439B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)

Abstract

L'INVENTION CONCERNE DES COMPOSÉS D'URÉE SUBSTITUÉS UTILISÉS DANS LE TRAITEMENT DE MALADIES ET DE TROUBLES LIÉS À DES DOMMAGES À L'ADN OU DES LÉSIONS DANS LA RÉPLICATION DE L'ADN. CETTE INVENTION A AUSSI POUR OBJET DES MÉTHODES DE CONCEPTION DES COMPOSÉS ET LEUR UTILISATION EN TANT QU'AGENTS THÉRAPEUTIQUES, PAR EXEMPLE, DANS LE TRAITEMENT DE CANCER ET D'AUTRES MALADIES CARACTÉRISÉES PAR DES DÉFAUTS DANS LA RÉPLICATION DE L'ADN, LA SÉGRÉGATION CHROMOSOMIQUE OU LA DIVISION CELLULAIRE.
MA30325A 2005-03-29 2007-10-26 Derives d'uree d'heteroaryle utilises pour inhiber chk1 MA29439B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66602605P 2005-03-29 2005-03-29

Publications (1)

Publication Number Publication Date
MA29439B1 true MA29439B1 (fr) 2008-05-02

Family

ID=36677174

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30325A MA29439B1 (fr) 2005-03-29 2007-10-26 Derives d'uree d'heteroaryle utilises pour inhiber chk1

Country Status (31)

Country Link
US (1) US8093244B2 (fr)
EP (2) EP1869020B1 (fr)
JP (2) JP5117374B2 (fr)
KR (2) KR20090031459A (fr)
CN (2) CN102219784A (fr)
AR (1) AR056645A1 (fr)
AT (1) ATE490248T1 (fr)
AU (1) AU2006230337B2 (fr)
BR (1) BRPI0609667A2 (fr)
CA (1) CA2602199C (fr)
CR (1) CR9395A (fr)
CY (1) CY1111240T1 (fr)
DE (1) DE602006018590D1 (fr)
DK (1) DK1869020T3 (fr)
EA (1) EA011287B1 (fr)
ES (1) ES2356068T3 (fr)
HR (1) HRP20100678T1 (fr)
IL (1) IL185481A0 (fr)
MA (1) MA29439B1 (fr)
MX (1) MX2007012116A (fr)
NO (1) NO20074944L (fr)
NZ (1) NZ561458A (fr)
PL (1) PL1869020T3 (fr)
PT (1) PT1869020E (fr)
RS (1) RS51616B (fr)
SI (1) SI1869020T1 (fr)
TN (1) TNSN07369A1 (fr)
TW (1) TWI375559B (fr)
UA (1) UA92164C2 (fr)
WO (1) WO2006105262A1 (fr)
ZA (1) ZA200707715B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5221367A (en) 1988-08-03 1993-06-22 International Business Machines, Corp. Strained defect-free epitaxial mismatched heterostructures and method of fabrication
UA95310C2 (ru) * 2006-10-20 2011-07-25 Айкос Корпорейшен Композиция, содержащая ингибитор chk1 и циклодекстрин, для лечения рака
CN101200429B (zh) * 2006-12-13 2012-08-22 上海睿智化学研究有限公司 2-硝基-4,5-二卤代苯酚类和2-氨基-4,5-二卤代苯酚类及其盐及其合成方法
GB201008005D0 (en) 2010-05-13 2010-06-30 Sentinel Oncology Ltd Pharmaceutical compounds
CA2928568A1 (fr) 2013-07-26 2015-01-29 Update Pharma Inc. Procedes combinatoires permettant d'ameliorer l'avantage therapeutique du bisantrene
PL3157566T3 (pl) 2014-06-17 2019-10-31 Vertex Pharma Metoda leczenia nowotworu przy użyciu kombinacji inhibitorów chk1 i atr
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
KR102678021B1 (ko) 2015-09-30 2024-06-26 버텍스 파마슈티칼스 인코포레이티드 Dna 손상제와 병용되는, atr 저해제를 포함하는 암 치료용 약제학적 조성물
CN108601781B (zh) 2016-02-04 2019-11-22 广州必贝特医药技术有限公司 作为检测点激酶1(chk1)抑制剂的3,5-二取代吡唑及其制备及应用
ES3057783T3 (en) 2016-03-15 2026-03-04 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
US20200108074A1 (en) * 2017-03-31 2020-04-09 Seattle Genetics, Inc. Combinations of chk1- and wee1- inhibitors
EP3461480A1 (fr) 2017-09-27 2019-04-03 Onxeo Combinaison d'inhibiteurs de point de contrôle du cycle cellulaire de réponse à un dommage à l'adn et de belinostat pour traiter le cancer
CN112457306A (zh) 2019-09-06 2021-03-09 上海瑛派药业有限公司 3,5-二取代吡唑化合物作为激酶抑制剂及其应用
WO2021183973A1 (fr) * 2020-03-13 2021-09-16 Research Development Foundation Méthodes de diagnostic et de traitement de cancers

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4293552A (en) 1978-02-27 1981-10-06 Eli Lilly And Company Novel 1-(mono-o-substituted benzoyl)-3-(substituted pyrazinyl) ureas
US6174993B1 (en) 1997-05-21 2001-01-16 The Children's Medical Center Corp. Short peptides which selectively modulate the activity of serine/threonine kinases
US6218109B1 (en) 1997-09-05 2001-04-17 Baylor College Of Medicine Mammalian checkpoint genes and proteins
GB9718952D0 (en) 1997-09-05 1997-11-12 Medical Res Council Mammalian chk1 effector cell cycle checkpoint protein kinase materials and methods
CA2304565A1 (fr) 1997-10-06 1999-04-15 Basf Aktiengesellschaft Derives d'indeno(1,2-c)-, de naphto(1,2-c)-, et de benzo(6,7)cyclohepta(1,2-c)pyrazole
JP2002526450A (ja) 1998-09-18 2002-08-20 スミスクライン・ビーチャム・コーポレイション Ｃｈｋ１キナーゼ阻害物質
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
AU3974001A (en) 2000-02-03 2001-08-14 Ali R. Fattaey Method and reagent for the inhibition of checkpoint kinase-1 (chk 1) enzyme
WO2001062900A1 (fr) 2000-02-25 2001-08-30 The Regents Of The University Of California. Scytonemine et ses procedes d'utilisation
US6211164B1 (en) 2000-03-10 2001-04-03 Abbott Laboratories Antisense oligonucleotides of the human chk1 gene and uses thereof
US6534691B2 (en) 2000-07-18 2003-03-18 E. I. Du Pont De Nemours And Company Manufacturing process for α-olefins
WO2002016326A1 (fr) 2000-08-18 2002-02-28 Agouron Pharmaceuticals, Inc. Hydroxyimino-fluorenes heterocycliques et leur utilisation pour inhiber des proteines kinases
CA2434066A1 (fr) 2001-01-26 2002-09-12 Pharmacia Italia S.P.A. Derives de chromane, procede de preparation et d'utilisation de ces derives en tant qu'agents antitumoraux
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
US7064215B2 (en) 2001-07-03 2006-06-20 Chiron Corporation Indazole benzimidazole compounds
WO2003028731A1 (fr) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Inhibiteurs de kinase chk1
WO2003029241A1 (fr) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Inhibiteurs de chk1 kinase
EP1448545B1 (fr) 2001-10-04 2008-11-19 Smithkline Beecham Corporation Inhibiteurs du facteur de transcription nf-kb
WO2003028724A1 (fr) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Inhibiteurs de la kinase chk1
AU2002356871A1 (en) 2001-10-30 2003-05-12 Pharmacia Corporation Heteroaromatic carboxamide derivatives for the treatment of inflammation
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US20030119839A1 (en) 2001-12-13 2003-06-26 Nan-Horng Lin Protein kinase inhibitors
CA2483496A1 (fr) 2002-04-26 2003-11-06 Warner-Lambert Company Llc Inhibiteurs de checkpoint kinases (wee1 et chk1)
US7202244B2 (en) * 2002-05-29 2007-04-10 Millennium Pharmaceuticals, Inc. Chk-1 inhibitors
US20040034038A1 (en) 2002-08-13 2004-02-19 Goaquan Li Urea kinase inhibitors
US7056925B2 (en) * 2002-08-13 2006-06-06 Abbott Laboratories Urea kinase inhibitors
CA2496164C (fr) 2002-08-23 2010-11-09 Chiron Corporation Quinolinones de benzimidazole et leurs utilisations
KR20050084027A (ko) 2002-11-28 2005-08-26 쉐링 악티엔게젤샤프트 Ｃｈｋ-, ｐｄｋ- 및 ａｋｔ-억제성 피리미딘, 그의제조방법 및 약제로서의 그의 용도
PL378372A1 (pl) 2003-01-09 2006-04-03 Pfizer Inc. Tricykliczne związki jako inhibitory kinaz białkowych do wzmacniania skuteczności środków przeciwnowotworowych i radioterapii
CA2571424A1 (fr) 2004-06-25 2006-02-02 Icos Corporation Derives de bisaryluree utiles pour inhiber chk1
CA2679908A1 (fr) 2009-09-23 2011-03-23 Shell Internationale Research Maatschappij B.V. Processus d'extraction de solvant en boucle fermee pour les sables bitumineux
CN104407475B (zh) 2014-12-04 2017-04-05 厦门天马微电子有限公司 液晶显示面板

Also Published As

Publication number Publication date
CN101151259A (zh) 2008-03-26
CN101151259B (zh) 2011-06-15
CY1111240T1 (el) 2015-06-11
ES2356068T3 (es) 2011-04-04
JP2009227682A (ja) 2009-10-08
KR100912998B1 (ko) 2009-08-20
PT1869020E (pt) 2010-12-23
US8093244B2 (en) 2012-01-10
EP2330105A1 (fr) 2011-06-08
EA200702094A1 (ru) 2008-02-28
NZ561458A (en) 2011-03-31
TWI375559B (en) 2012-11-01
BRPI0609667A2 (pt) 2010-04-20
ZA200707715B (en) 2009-09-30
MX2007012116A (es) 2008-04-08
UA92164C2 (ru) 2010-10-11
CA2602199C (fr) 2013-09-10
PL1869020T3 (pl) 2011-05-31
TNSN07369A1 (en) 2008-12-31
KR20090031459A (ko) 2009-03-25
JP5117374B2 (ja) 2013-01-16
KR20070107178A (ko) 2007-11-06
CR9395A (es) 2008-03-31
AR056645A1 (es) 2007-10-17
IL185481A0 (en) 2008-01-06
RS51616B (sr) 2011-08-31
EP1869020B1 (fr) 2010-12-01
DK1869020T3 (da) 2011-01-24
SI1869020T1 (sl) 2011-02-28
HRP20100678T1 (hr) 2011-02-28
EA011287B1 (ru) 2009-02-27
NO20074944L (no) 2007-10-24
CN102219784A (zh) 2011-10-19
DE602006018590D1 (de) 2011-01-13
CA2602199A1 (fr) 2006-10-05
TW200722090A (en) 2007-06-16
US20090143357A1 (en) 2009-06-04
WO2006105262A1 (fr) 2006-10-05
HK1119670A1 (en) 2009-03-13
ATE490248T1 (de) 2010-12-15
AU2006230337A1 (en) 2006-10-05
EP1869020A1 (fr) 2007-12-26
AU2006230337B2 (en) 2011-10-27
JP2008535830A (ja) 2008-09-04

Similar Documents

Publication Publication Date Title
MA29692B1 (fr) Derives de la xanthine en tant qu'agonistes selectifs du hm74a
MA32300B1 (fr) Anticorps anti-facteur d humanises et utilisations de ceux-ci
MA31260B1 (fr) 3-imidazolyl-indoles pour le traitement de maladies proliferatives
EP1841426A4 (fr) Carbinamines tertiaires incluant des heterocycles substitues, agissant en tant qu'inhibiteurs de la beta-secretase et utilisees dans le traitement de la maladie d'alzheimer
MA29568B1 (fr) Composes d'azaindazole et methodes d'utilisation desdits composes
EP1651623A4 (fr) Hexahydrodiazepinones utilises en tant qu'inhibiteurs de la dipeptidyl peptidase iv pour le traitement ou la prevention du diabete
TN2009000551A1 (fr) Nouveaux composes chimiques
ATE440087T1 (de) 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
MA30340B1 (fr) Nouveaux composes
EP1673078A4 (fr) Inhibiteurs de type benzylether et benzylamino de beta-secretase pour le traitement de la maladie d'alzheimer
MA27675A1 (fr) Derives de piperazine et leur utilisation dans le traitement de maladies neurologiques et psychiatriques
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
NO20064726L (no) Imidazolforbindelser for behandling av neurodegenerative forstyrrelser
MA33606B1 (fr) Dérivés de pyrimidine en tant qu'inhibiteurs de protéine tyrosine kinase 2
MA31283B1 (fr) Produits dérivés de 2,3-dihydroimidazo[1,2-c]quinazoline substitués, utiles pour le traitement de troubles hyperlifératifs et de maladies associées à une angiogénèse
MA27482A1 (fr) Piperazines, (1,4) diazepines, et 2,5-diazabicyclo (2.2.1) heptanes substitues en tant qu'antagonistes de l'histamine h1 et/ou h3 ou antagonistes inverses de l'histamine h3
EP1888066A4 (fr) Aminocyclohexanes en tant qu'inhibiteurs de dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete
EP1624874A4 (fr) Derives d'acide 3-amino-4-phenylbutanoique en tant qu'inhibiteurs de dipeptidyl peptidase dans le cadre du traitement ou de la prevention du diabete
CY1111086T1 (el) Παραγωγα 2-αμινο-κιναζολινης χρησιμα ως αναστολεις της βητα-σεκρετασης (bace)
EP1784188A4 (fr) Derives de triazole accoles inhibiteurs de la dipeptidyl peptidase-iv utilises dans le traitement ou la prevention du diabete
MA30041B1 (fr) Immunoglobulines
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
BRPI0509391A (pt) piridonas substituìdos como inibidores de poli(adp-ribose) polimerase (parp)
CL2007002899A1 (es) Compuestos derivados de azaciclilaminas n-sustituidas, inhibidores del receptor de histamina 3; proceso de preparacion; composicion farmaceutica que comprende los compuestos, y usopara el tratamiento de trastornos cognitivos, esquizofre nia y enfermedad de alzheimer entre otros.
EP2091328A4 (fr) Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer